Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
A prospective clinical trial with the aim of maintaining drug efficacy of natalizumab while
extending dose intervals guided by drug concentrations in patients with relapsing remitting
multiple sclerosis.
Phase:
Phase 4
Details
Lead Sponsor:
VU University Medical Center
Collaborators:
Erasmus Medical Center OLVG Rijnstate Hospital Sanquin Sanquin Plasma Products BV St. Antonius Hospital